Therefore, more detailed understanding of both host- and tumor-related factors that predict the response to this mAb may result in the novel design of CD26-based immunotherapeutic approach for boosting cytotoxic efficacy in RRMM. This evidence concerns the gene DPP4 and neoplasm.